MDT-AP-0599
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 44.04
- os_event
- false
- age_years
- 12
- sex
- M
- new_clusters
- S2
- umap1_2d
- -0.921449749
- umap2_2d
- -9.529103211
- umap1_3d
- -3.4323092
- umap2_3d
- -1.396679654
- umap3_3d
- 5.365551839
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.630
- MYC_TARGETS_V1+0.540
- E2F_TARGETS+0.510
- G2M_CHECKPOINT+0.450
- UNFOLDED_PROTEIN_RESPONSE+0.370
- DNA_REPAIR+0.290
- ALLOGRAFT_REJECTION+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- INFLAMMATORY_RESPONSE+0.260
- MTORC1_SIGNALING+0.240
Top 10 suppressed
- NOTCH_SIGNALING-0.380
- HEDGEHOG_SIGNALING-0.290
- HEME_METABOLISM-0.250
- TGF_BETA_SIGNALING-0.250
- WNT_BETA_CATENIN_SIGNALING-0.170
- FATTY_ACID_METABOLISM-0.140
- XENOBIOTIC_METABOLISM-0.130
- MYOGENESIS-0.120
- P53_PATHWAY-0.120
- SPERMATOGENESIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3B6-01A-21R-A20F-07 | — | — | 0.804 |
| 2 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.803 |
| 3 | X29cb9797.16bb.49a5.bb14.fd9e9d48bbb4 | — | cohortA1 | 0.791 |
| 4 | BS_DHA5FMVW | ATRT | — | 0.787 |
| 5 | SRR6013572 | — | cohortSQ1 | 0.785 |
| 6 | BS_5CTVXVRX | high-grade glioma | — | 0.785 |
| 7 | R152 | — | — | 0.773 |
| 8 | SRR26320090 | — | — | 0.773 |
| 9 | DRR168607 | — | — | 0.772 |
| 10 | SRR934852 | — | — | 0.768 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.050 | Inavolisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |